Header Logo

Connection

George Reed to Arthritis, Rheumatoid

Back to Details
This is a "connection" page, showing publications George Reed has written about Arthritis, Rheumatoid.
George Reed
Connection Strength
8.821
Arthritis, Rheumatoid
  1. Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold LR, Feathers VL, Shadick N, Weinblatt ME, Reed G. The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. J Rheumatol. 2021 12; 48(12):1776-1783.
    View in: PubMed
    Score: 0.526
  2. Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S. Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis. Arthritis Res Ther. 2017 04 27; 19(1):81.
    View in: PubMed
    Score: 0.409
  3. Rathbun AM, Harrold LR, Reed GW. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers. Clin Ther. 2016 Jul; 38(7):1759-1772.e3.
    View in: PubMed
    Score: 0.386
  4. Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015 May; 67(6):765-75.
    View in: PubMed
    Score: 0.356
  5. Rathbun AM, Harrold LR, Reed GW. Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms. Clin Rheumatol. 2015 Apr; 34(4):653-63.
    View in: PubMed
    Score: 0.340
  6. Rathbun AM, Harrold LR, Reed GW. A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population. Clin Exp Rheumatol. 2014 Jul-Aug; 32(4):523-32.
    View in: PubMed
    Score: 0.336
  7. Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1707-12.
    View in: PubMed
    Score: 0.319
  8. Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-a antagonist therapies. Clin Exp Rheumatol. 2013 Mar-Apr; 31(2):189-94.
    View in: PubMed
    Score: 0.302
  9. Bentley MJ, Greenberg JD, Reed GW. A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. J Rheumatol. 2010 Aug 01; 37(8):1607-14.
    View in: PubMed
    Score: 0.255
  10. Bentley MJ, Reed GW. Simplified composite disease activity measures in rheumatoid arthritis: should they be used in standard care? Clin Exp Rheumatol. 2008 Mar-Apr; 26(2):358-66.
    View in: PubMed
    Score: 0.217
  11. Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar; 77(3):263-271.
    View in: PubMed
    Score: 0.173
  12. Spandorfer R, Kane K, Pappas DA, Kremer J, Reed G, Curtis JR, Navarro-Mill?n I. New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry. Semin Arthritis Rheum. 2025 02; 70:152559.
    View in: PubMed
    Score: 0.172
  13. Pappas DA, Reed G, Kane K, Curtis JR, Charles-Schoeman C, Giles JT, Kremer JM. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients. Semin Arthritis Rheum. 2024 10; 68:152504.
    View in: PubMed
    Score: 0.168
  14. Aripova N, Kremer JM, Pappas DA, Reed G, England BR, Robinson BH, Curtis JR, Thiele GM, Mikuls TR. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford). 2024 02 01; 63(2):542-550.
    View in: PubMed
    Score: 0.163
  15. Bessette L, Movahedi M, Reed G, Kremer JM, Kane K, Keystone E. Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis? J Clin Rheumatol. 2023 Oct 01; 29(7):332-340.
    View in: PubMed
    Score: 0.159
  16. Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 11; 74(11):1909-1916.
    View in: PubMed
    Score: 0.147
  17. Baker JF, Reed G, Kremer J. Weight Fluctuation and the Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 02; 74(2):229-235.
    View in: PubMed
    Score: 0.142
  18. Kremer JM, Reed G, Pappas DA, Kane K, Feathers VL, Weinblatt ME, Shadick N, Greenberg J, Harrold LL. Dr. Kremer et al reply. J Rheumatol. 2022 03; 49(3):338-339.
    View in: PubMed
    Score: 0.139
  19. Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.
    View in: PubMed
    Score: 0.137
  20. Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021 12; 80(12):1522-1529.
    View in: PubMed
    Score: 0.137
  21. Kremer JM, Reed G, Pappas DA, Harold LR, Kane K, Greenberg J, Winthrop K. Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open. 2020 11; 6(3).
    View in: PubMed
    Score: 0.130
  22. Cohen SB, Kremer JM, Dandreo KJ, Reed GW, Magner R, Shan Y, Kafka S, DeHoratius RJ, Ellis L, Parenti D. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clin Rheumatol. 2019 Sep; 38(9):2501-2508.
    View in: PubMed
    Score: 0.118
  23. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019; 14(1):e0210459.
    View in: PubMed
    Score: 0.115
  24. Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol. 2018 Sep; 37(9):2331-2340.
    View in: PubMed
    Score: 0.110
  25. Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 03; 70(3):379-387.
    View in: PubMed
    Score: 0.108
  26. Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, Saunders KC, Ganguli A. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. Rheumatology (Oxford). 2017 07 01; 56(7):1095-1101.
    View in: PubMed
    Score: 0.104
  27. Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care Res (Hoboken). 2016 12; 68(12):1888-1893.
    View in: PubMed
    Score: 0.099
  28. Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016 12 01; 18(1):280.
    View in: PubMed
    Score: 0.099
  29. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016 Apr 26; 18:94.
    View in: PubMed
    Score: 0.095
  30. Michaud K, Berglind N, Franz?n S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Askling J. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis. 2016 10; 75(10):1797-805.
    View in: PubMed
    Score: 0.094
  31. Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). 2015 Dec; 67(12):1671-8.
    View in: PubMed
    Score: 0.093
  32. Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care Res (Hoboken). 2015 Dec; 67(12):1637-45.
    View in: PubMed
    Score: 0.093
  33. Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SM, Yamanaka H, Wesby-van Swaay E, Symmons D. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Ann Rheum Dis. 2016 Oct; 75(10):1789-96.
    View in: PubMed
    Score: 0.093
  34. Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed G, Saeki Y, Tohma S, Kremer J, Solomon DH. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. J Rheumatol. 2015 Dec; 42(12):2238-46.
    View in: PubMed
    Score: 0.092
  35. Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015 Sep 18; 17:256.
    View in: PubMed
    Score: 0.091
  36. Nyberg F, Askling J, Berglind N, Franz?n S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Greenberg JD. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiol Drug Saf. 2015 Nov; 24(11):1121-32.
    View in: PubMed
    Score: 0.091
  37. Kaushik P, Solomon DH, Greenberg JD, Anderson JT, Reed G, Pala O, Sumbul-Yuksel B, Kadam P, Kremer JM. Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. Clin Rheumatol. 2015 Oct; 34(10):1697-704.
    View in: PubMed
    Score: 0.091
  38. Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015 Jul; 42(7):1090-8.
    View in: PubMed
    Score: 0.089
  39. Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis. 2015 Jun; 74(6):1150-5.
    View in: PubMed
    Score: 0.087
  40. Harrold LR, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, Kremer JM. The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network. BMC Musculoskelet Disord. 2014 Nov 21; 15:389.
    View in: PubMed
    Score: 0.086
  41. Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, Fisher MC, Greenberg JD, Putterman C, Mease PJ, Gottlieb AB, Kremer JM, Broder A. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014 Jun; 66(6):1472-81.
    View in: PubMed
    Score: 0.084
  42. Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, Putterman C, Broder A. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Apr; 66(4):600-7.
    View in: PubMed
    Score: 0.083
  43. Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". BMC Musculoskelet Disord. 2014 Apr 01; 15:113.
    View in: PubMed
    Score: 0.083
  44. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014 Feb 03; 16(1):R40.
    View in: PubMed
    Score: 0.082
  45. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015 Feb; 74(2):430-6.
    View in: PubMed
    Score: 0.081
  46. Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, Yazici Y, Ogedegbe G, Harrold LR. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013 Dec; 126(12):1089-98.
    View in: PubMed
    Score: 0.081
  47. Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014 Feb; 43(4):489-97.
    View in: PubMed
    Score: 0.079
  48. Dewitt EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD. Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. J Rheumatol. 2013 Feb; 40(2):127-36.
    View in: PubMed
    Score: 0.076
  49. Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology (Oxford). 2013 Oct; 52(10):1785-94.
    View in: PubMed
    Score: 0.076
  50. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1811-8.
    View in: PubMed
    Score: 0.075
  51. Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord. 2012 May 31; 13:85.
    View in: PubMed
    Score: 0.073
  52. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar; 64(3):630-8.
    View in: PubMed
    Score: 0.072
  53. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul; 71(7):1134-42.
    View in: PubMed
    Score: 0.071
  54. Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken). 2011 Dec; 63(12):1672-9.
    View in: PubMed
    Score: 0.070
  55. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
    View in: PubMed
    Score: 0.068
  56. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May; 70(5):785-91.
    View in: PubMed
    Score: 0.066
  57. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Apr; 70(4):576-82.
    View in: PubMed
    Score: 0.066
  58. Reddy SM, Anandarajah AP, Fisher MC, Mease PJ, Greenberg JD, Kremer JM, Reed G, Chen R, Messing S, Kaukeinen K, Ritchlin CT. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol. 2010 Dec; 37(12):2566-72.
    View in: PubMed
    Score: 0.065
  59. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep; 69(9):1612-7.
    View in: PubMed
    Score: 0.063
  60. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010 Nov; 69(11):1920-5.
    View in: PubMed
    Score: 0.063
  61. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010 Jan 15; 62(1):101-7.
    View in: PubMed
    Score: 0.062
  62. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009 Jun; 15(4):155-60.
    View in: PubMed
    Score: 0.059
  63. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 Jun; 48(6):686-90.
    View in: PubMed
    Score: 0.059
  64. Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, Kremer JM, Furst DE. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol. 2008 Oct; 35(10):1966-71.
    View in: PubMed
    Score: 0.056
  65. Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, Kafka SP, Reed G, Kremer JM. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med. 2008 Jun; 121(6):532-8.
    View in: PubMed
    Score: 0.055
  66. Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer J. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum. 2006 Aug 15; 55(4):543-50.
    View in: PubMed
    Score: 0.049
  67. Greenberg JD, Bingham CO, Abramson SB, Reed G, Sebaldt RJ, Kremer J. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum. 2005 Feb 15; 53(1):12-7.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.